Salvatore T, Pafundi PC, Galiero R, Albanese G, Di Martino A, Caturano A, Vetrano E, Rinaldi L, Sasso FC. The diabetic cardiomyopathy: the contributing pathophysiological mechanisms. Front Med (Lausanne). 2021;8:695792.
Smith ML, Bull CJ, Holmes MV, Davey Smith G, Sanderson E, Anderson EL, Bell JA. Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse mendelian randomization study. EBioMedicine. 2023;90:104503.
Couturier A, Calissi C, Cracowski JL, Sigaudo-Roussel D, Khouri C, Roustit M. Mouse models of diabetes-related ulcers: a systematic review and network meta-analysis. EBioMedicine. 2023;98:104856.
Jiang T, Li Y, He S, Huang N, Du M, Zhai Q, Pu K, Wu M, Yan C, Ma Z, Wang Q. Reprogramming astrocytic NDRG2/NF-κB/C3 signaling restores the diabetes-associated cognitive dysfunction. EBioMedicine. 2023;93:104653.
Dewidar B, Mastrototaro L, Englisch C, Ress C, Granata C, Rohbeck E, Pesta D, Heilmann G, Wolkersdorfer M, Esposito I, Reina Do Fundo M, Zivehe F, Yavas A, Roden M. Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases. EBioMedicine. 2023;94:104714.
Chen J, Chang J, Shi Q, Li X, Wang L, Zhao H. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study. BMC Cardiovasc Disord. 2023;23(1):495.
Liu Y, Zhong W, Li X, Shen F, Ma X, Yang Q, Hong S, Sun Y, Diets. Gut microbiota and metabolites. Phenomics. 2023;3(3):268–84.
Dubois-Deruy E, Peugnet V, Turkieh A, Pinet F. Oxidative stress in cardiovascular diseases. Antioxid (Basel). 2020;9:864.
van der Pol A, van Gilst WH, Voors AA, van der Meer P. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2019;4:425–35.
Nikolaienko R, Bovo E, Zima AV. Redox dependent modifications of ryanodine receptor: basic mechanisms and implications in heart diseases. Front Physiol. 2018;9:1775.
Tian C-J, Zhen Z. Reactive carbonyl species: diabetic complication in the heart and lungs. Trends Endocrinol Metab. 2019;8:546–56.
Singh A, Kukreti R, Saso L, Kukreti S. Mechanistic insight into oxidative stress-triggered signaling pathways and type 2 diabetes. Molecules. 2022;27(3):950.
Moore CJ, Shao CH, Nagai R, Kutty S, Singh J, Bidasee KR. Malondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetes. Mol Cell Biochem. 2013;376(1–2):121–35.
Crudele L, Gadaleta RM, Cariello M, Moschetta A. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine. 2023;97:104821.
Tian C, Shao CH, Moore CJ, Kutty S, Walseth T, DeSouza C, Bidasee KR. Gain of function of cardiac ryanodine receptor in a rat model of type 1 diabetes. Cardiovasc Res. 2011;2:300–9.
Asghari P, Scriven DR, Ng M, Panwar P, Chou KC, van Petegem F, Moore ED. Cardiac ryanodine receptor distribution is dynamic and changed by auxiliary proteins and post-translational modification. Elife. 2020;9:e51602.
Kushnir A, Shan J, Betzenhauser MJ, Reiken S, Marks AR. Role of CaMKIIδ phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. PNAS. 2010;22:10274–9.
Tian C-J, Zhang JH, Liu J, Ma Z, Zhen Z. Ryanodine receptor and immune-related molecules in diabetic cardiomyopathy. ESC Heart Fail. 2021;8(4):2637–46.
Shuey MM, Lee KM, Keaton J, Khankari NK, Breeyear JH, Walker VM, Miller DR, Heberer KR, Reaven PD, Clarke SL, Lee J, Lynch JA, Vujkovic M, Edwards TL. A genetically supported drug repurposing pipeline for diabetes treatment using electronic health records. EBioMedicine. 2023;94:104674.
Zhang X, Sun J, Wang J, Meng T, Yang J, Zhou Y. The role of ferroptosis in diabetic cardiovascular diseases and the intervention of active ingredients of traditional Chinese medicine. Front Pharmacol. 2023;14:1286718.
Trotta MC, Herman H, Ciceu A, Mladin B, Rosu M, Lepre CC, Russo M, Bácskay I, Fenyvesi F, Marfella R, Hermenean A, Balta C, D’Amico M. Chrysin-based supramolecular cyclodextrin-calixarene drug delivery system: a novel approach for attenuating cardiac fibrosis in chronic diabetes. Front Pharmacol. 2023;14:1332212.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem. 1976;72:248–54.
Bai L, Gao J, Wei F, Zhao J, Wang D, Wei J. Therapeutic potential of ginsenosides as an adjuvant treatment for diabetes. Front Pharmacol. 2018;9:423.
Dong C, Liu P, Wang H, Dong M, Li G, Li Y. Ginsenoside Rb1 attenuates diabetic retinopathy in streptozotocin-induced diabetic rats. Acta Cir Bras. 2019;34(2):e201900201.
Fan W, Huang Y, Zheng H, Li S, Li Z, Yuan L, Cheng X, He C, Sun J. Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: pharmacology and mechanisms. Biomed Pharmacother. 2020;132:110915.
Su H, Tian C-J, Wang Y, Shi J, Chen X, Zhen Z, Bai Y, Deng L, Feng C, Ma Z, Liu J. Ginsenoside Rb1 reduces oxidative/carbonyl stress damage and ameliorates inflammation in the lung of streptozotocin-induced diabetic rats. Pharm Biol. 2022;60(1):2229–36.
Qin L, Wang J, Zhao R, Zhang X, Mei Y. Ginsenoside-Rb1 improved diabetic cardiomyopathy through regulating calcium signaling by alleviating protein O-GlcNAcylation. J Agric Food Chem. 2019;51:14074–85.
Zhou WJ, Li JL, Zhou QM, Cai FF, Chen XL, Lu YY, Zhao M, Su SB. Ginsenoside Rb1 pretreatment attenuates myocardial ischemia by reducing calcium/calmodulin-dependent protein kinase II-medicated calcium release. World J Tradit Chin Med. 2020;6:284–94.
Alomar FA, Al-Rubaish A, Al-Muhanna F, Al-Ali AK, McMillan J, Singh J, Bidasee KR. Adeno-Associated viral transfer of Glyoxalase-1 blunts carbonyl and oxidative stresses in hearts of type 1 Diabetic rats. Antioxid (Basel). 2020;9(7):592.
Shao CH, Tian C, Ouyang S, Moore CJ, Alomar F, Nemet I, D’Souza A, Nagai R, Kutty S, Rozanski GJ, Ramanadham S, Singh J, Bidasee KR. Carbonylation induces heterogeneity in cardiac ryanodine receptors (RyR2) function during diabetes. Mol Pharmacol. 2013;3:383–99.
Bidasee KR, Nallani K, Besch HR, Dincer UD. Streptozotocin induced diabetes increases disulfide bond formation on cardiac ryanodine receptor (RyR2). J Pharmacol Exp Ther. 2003;305:989–98.
Ma S, Li X, Dong L, Zhu J, Zhang H, Jia Y. Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity in rats. BMC Complement Altern Med. 2016;16:61.
Bugger H, Schwarzer M, Chen D, Schrepper A, Amorim PA, Schoepe M, Nguyen TD, Mohr FW, Khalimonchuk O, Weimer BC, Doenst T. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res. 2010;2:376–84.
Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 2002;6:1938–48.
Barouch LA, Gao D, Chen L, Miller KL, Xu W, Phan AC, Kittleson MM, Minhas KM, Berkowitz DE, Wei C, Hare JM. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res. 2006;1:119–24.
Tian J, Tang W, Xu M, Zhang C, Zhao P, Cao T, Shan X, Lu R, Guo W. Shengmai San alleviates diabetic cardiomyopathy through improvement of mitochondrial lipid metabolic disorder. Cell Physiol Biochem. 2018;5:1726–39.
Ding K, Song C, Hu H, Yin K, Huang H, Tang H. The Role of NLRP3 inflammasome in diabetic cardiomyopathy and its therapeutic implications. Oxid Med Cell Longev. 2022;2022.
Luo B, Huang F, Liu Y, Liang Y, Wei Z, Ke H, Zeng Z, Huang W, He Y NLRP3 Inflammasome as a molecular marker in diabetic cardiomyopathy. Front Physiol. 2017;8:519.
Sharma A, Tate M, Mathew G, Vince JE, Ritchie RH, de Haan JB Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol. 2018;9:114.
D’Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A, Laviola L, Giorgino F The role of oxidative stress in cardiac disease: from physiological response to injury factor. Oxid Med Cell Longev. 2020;2020:5732956.
De Geest B, Mishra M. Role of oxidative stress in diabetic cardiomyopathy. Antioxidants(Basel). 2022;4:784.
Varun K, Zoltan K, Alba S, Manuel B, Elisabeth K, Dimitrios T, Jan B G, Maik B,Khurrum S, Berend I, Stephen H, Thomas F, Julia S, Peter N, Stefan K. Elevated markers of DNA damage and senescence are associated with the progression of albuminuria and restrictive lung disease in patients with type 2 diabetes. E Bio Medicine. 2023;90:104516.
Ferdinando G, and Brownlee M. Oxidative stress and diabetic complications.Circ Res. 2010;9:1058–1070.
Donoso P, Sanchez G, Bull R, Hidalgo C Modulation of cardiac ryanodine receptor activity by ROS and RNS. Front Biosci. 2011;2:553 – 67.
Shao CH, Wehrens XH, Wyatt TA, Parbhu S, Rozanski GJ, Patel KP, Bidasee KR. Exercise training during diabetes attenuates cardiac ryanodine receptor dysregulation. J Appl Physiol. 2009;106:1280–1292.
Nolla-Colomer C, Tarifa C, Llach A, Jimenez-Sabado V, Vallmitjana A, Casabella S, Colino H, Izquierdo P, Casellas S, Rodriguez-Font E, Cinca J, Chen SR W, Benitez R, Hove-Madsen L. Pathological phosphorylation of the ryanodine receptor at s2808 increases the number of individual clusters activated per calcium spark and the calcium released per cluster. Eur Heart J. 2020;Supplement 2: ehaa946.3689.
Fernandez-Miranda G, Romero-Garcia T, Barrera-Lechuga TP, Mercado-Morales M, and Rueda A. Impaired activity of ryanodine receptors contributes to calcium mishandling in cardiomyocytes of metabolic syndrome rats. Physiol. 2019;10:520.
Add Comment